The study team from the University of California, San Francisco (UCSF) Medical Center has completed patient enrollment for a Phase II Part I clinical trial testing the efficacy of an investigational drug called ABV-1505 for the treatment of adult attention-deficit hyperactivity disorder (ADHD). According to the sponsor, recent Phase II results from Stanford and other major centers revealed encouraging results for ABV-1505, with the active pharmaceutical ingredient PDC-1421, for treating major depressive disorder (MDD).
The Problem: ADHD
A mental disorder of the neurodevelopmental type, it is characterized by challenges involving paying attention, excessive activity and at times acting without regards to consequences which would otherwise not be appropriate for the age group. Some individuals struggling with ADHD have a hard time regulating emotions or have problems with executive function. Often, ADHD is also associated with other issues, such as substance abuse.
According to the ADHD Institute, the mean worldwide prevalence of ADHD is 2.2% overall (range: 01.-8.1%) has been estimated in children and adolescents (18 and under). The mean prevalence of ADHD in adults (18-4...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).